Neuroprotective peptide that binds to amyloid beta (Aβ). Protects neurons against toxic effects of Aβ (1-42) in vitro and in vivo. Potential therapeutic in the treatment of Alzheimer's Disease.
(Modifications: Asp-5 = C-terminal amide)
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 2 mg/ml in 10% acetonitrile / water|
Preparing Stock Solutions
The following data is based on the product molecular weight 652.75. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.53 mL||7.66 mL||15.32 mL|
|5 mM||0.31 mL||1.53 mL||3.06 mL|
|10 mM||0.15 mL||0.77 mL||1.53 mL|
|50 mM||0.03 mL||0.15 mL||0.31 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Szegedi et al (2005) Pentapeptides derived from Aβ1-42 protect neurons from the modulatory effects of Aβ fibrils- an in vitro and in vivo electrophysiological study. Neurobiology of Disease 18 499 PMID: 15755677
If you know of a relevant reference for LPYFD-NH2, please let us know.
View Related Products by Target
Keywords: LPYFD-NH2, supplier, LPYFDNH2, neuroprotective, amyloid, sequence-derived, peptides, binds, amyloid, beta, Ab, Aβ, Alzheimers, amyloidbeta, amyloidb, amyloidβ, Amyloid, Beta, Peptides, Amyloid, Beta, Peptides, Tocris Bioscience
Citations for LPYFD-NH2
Citations are publications that use Tocris products.
Currently there are no citations for LPYFD-NH2. Do you know of a great paper that uses LPYFD-NH2 from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.